Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
M&A
Biotech
Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova
LaNova's PD-1xVEGF bispecific antibody was licensed to Merck in a $588 million upfront deal.
Angus Liu
Jul 15, 2025 10:16am
Fierce Pharma
Summit in high-stakes deal talks with AstraZeneca: Bloomberg
Jul 7, 2025 10:45am
Concentra strikes again, circling up IGM Biosciences
Jul 1, 2025 9:58am
AbbVie inks $2.1B Capstan buyout to enter in vivo CAR-T market
Jun 30, 2025 9:45am
Lilly lands next-gen pain asset in $1B SiteOne acquisition
May 27, 2025 11:30am
Julius attaches roots to Peachtree in CRO merger
May 14, 2025 2:52pm
